<DOC>
	<DOC>NCT00540436</DOC>
	<brief_summary>The primary objective of this study is to evaluate the effect of GSK1325760A on improvement in exercise capacity in subjects with pulmonary arterial hypertension (PAH). The secondary objectives of this study are to evaluate administration of GSK1325760A on: - The safety and tolerability - Improvement of PAH - The steady-state plasma pharmacokinetics of GSK1325760A</brief_summary>
	<brief_title>Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<criteria>Inclusion criteria: Subjects must have a diagnosis of Pulmonary Arterial Hypertension (PAH) in clinical classification of Pulmonary Hypertension Group1 The mean right heart catheterization parameters measured from 6 months prior to the administration of the investigational drug must meet the criteria below: Mean pulmonary arterial pressure (mPAP) of &gt;25 mmHg Pulmonary vascular resistance (PVR) of &gt;3 mmHg/L/min Mean pulmonary capillary wedge pressure or left ventricular end diastolic pressure of &lt;15 mmHg (if measurable) The measured six minutes walk distance (6MWD) at screening visit is in the range of =&gt;150m and &lt;=450m</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Ambrisentan</keyword>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>6MWD</keyword>
</DOC>